Circulating cfDNA and HPV as Prognostic Biomarkers for First-Line Recurrent Metastatic Cervical Cancer
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorZhejiang Cancer Hospital
About this trial
Primary Objective of this study: To investigate the correlation between longitudinal quantitative dynamics of circulating tumor DNA (ctDNA) and HPV-derived cell-free DNA (HPV cfDNA) in peripheral blood and clinical prognosis among patients with recurrent and metastatic cervical cancer who achieved complete response following standard first-line systemic therapy.
Eligibility criteria
Qualifiers
Histopathologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma;
Patients with first recurrent or metastatic cervical cancer (including primary stage IVB disease);
Received standard first-line therapy (TP/TC regimen plus immunotherapy ± bevacizumab);
Achieved complete response (CR) following standard first-line treatment;
Disqualifiers
History of other malignant tumors within the past 2 years;
Pregnant or breastfeeding women;
Severe concomitant diseases, including: cardiovascular diseases (e.g., uncontrolled heart failure, unstable angina, etc.); pulmonary diseases (e.g., severe chronic obstructive pulmonary disease, interstitial pneumonia and other conditions impairing respiratory function); hepatic and renal dysfunction (e.g., decompensated liver cirrhosis, severe renal failure requiring dialysis, etc.);
Refusal to sign informed consent;
Trial design
Treatments tested in this trial
- Biospecimen collection (peripheral blood and paraffin tumor tissue)
Treatment groups
60 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov